These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31842679)

  • 1. MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
    Cobo-Calvo A; Marignier R
    Mult Scler; 2020 Mar; 26(3):274-276. PubMed ID: 31842679
    [No Abstract]   [Full Text] [Related]  

  • 2. MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
    Leite MI; Sato DK
    Mult Scler; 2020 Mar; 26(3):272-274. PubMed ID: 31842686
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of Autoantibodies Against Myelin Oligodendrocyte Glycoprotein in Multiple Sclerosis and Related Diseases.
    Spadaro M; Meinl E
    Methods Mol Biol; 2016; 1304():99-104. PubMed ID: 25814289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and MRI phenotype of children with MOG antibodies.
    Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
    Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica: clinical value for diagnosis and disease activity.
    Xu Y; Zhang Y; Liu CY; Peng B; Wang JM; Zhang XJ; Li HF; Cui LY
    Chin Med J (Engl); 2012 Sep; 125(18):3207-10. PubMed ID: 22964310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease.
    Rosenthal JF; Hoffman BM; Tyor WR
    J Investig Med; 2020 Feb; 68(2):321-330. PubMed ID: 31582425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease.
    Salama S; Khan M; Levy M; Izbudak I
    Mult Scler Relat Disord; 2019 Apr; 29():15-22. PubMed ID: 30658259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.
    Konuskan B; Yildirim M; Gocmen R; Okur TD; Polat I; Kilic H; Saltik S; Ozturk Z; Gucuyener K; Altunbasak S; Celik T; Kose G; Yilmaz A; Komur M; Kayilioglu H; Anlar B
    Mult Scler Relat Disord; 2018 Nov; 26():1-7. PubMed ID: 30212767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOG CNS Autoimmunity and MOGAD.
    Moseley CE; Virupakshaiah A; Forsthuber TG; Steinman L; Waubant E; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200275. PubMed ID: 38996203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade.
    Yong KP; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34911792
    [No Abstract]   [Full Text] [Related]  

  • 12. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.
    Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M
    Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review.
    Gombolay GY; Gadde JA
    J Neuroimmunol; 2021 Sep; 358():577653. PubMed ID: 34229204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of MOG autoantibody-associated demyelinating diseases.
    Reindl M; Di Pauli F; Rostásy K; Berger T
    Nat Rev Neurol; 2013 Aug; 9(8):455-61. PubMed ID: 23797245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
    Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: A case for expanding anti-MOG testing?
    Breza M; Koutsis G; Tzartos JS; Velonakis G; Evangelopoulos ME; Tzanetakos D; Karagiorgou K; Angelopoulou G; Kasselimis D; Potagas C; Anagnostouli M; Stefanis L; Kilidireas C
    Mult Scler Relat Disord; 2019 Aug; 33():67-69. PubMed ID: 31158804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases.
    Rigal J; Ciron J; Lépine Z; Biotti D
    Mult Scler Relat Disord; 2020 Jun; 41():102019. PubMed ID: 32151983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.